Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 14/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12196101 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12196126 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12196125 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23960132 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| 1,3-Dicyclohexylurea SCHEMBL2755 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24308701 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15093798 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24308699 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15277551 | 0.97 | EPHX1 (0.94) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15277631 | 0.97 | EPHX1 (0.94) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1844767-B1 | Compounds complexing epoxide hydrolase and their use for treating inflammation | UNIV CALIFORNIA (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| EP-1844767-A2 | Epoxide hydrolase complexes and methods therewith | The Regents of the University of California (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1154764-B1 | USE OF EPOXIDE HYDROLASE COMPLEXES FOR TREATING HYPERTENSION | UNIV CALIFORNIA (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20060035869-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2006-02-16 | — | — | US | disclosed |
| EP-1154764-A4 | EPOXIDE HYDROLASE COMPLEXES AND METHODS THEREWITH | UNIV CALIFORNIA (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1154764-A1 | EPOXIDE HYDROLASE COMPLEXES AND METHODS THEREWITH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6150415-A | TREATING EPOXIDE HYDROLASE TO PURIFY, ISOLATE OR INHIBIT THE ENZYME BY CONTACTING A UREA DERIVATIVE OR OTHER SPECIFIED COMPOUNDS IN FREE OR IMMOBILIZED FORM WITH THE ACTIVE ENZYME TO FORM A COMPLEX WHICH MODIFYS THE ENZYME ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000048593-A1 | EPOXIDE HYDROLASE COMPLEXES AND METHODS THEREWITH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885NPC1 2648/4885 |
| US-20060035869-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885NPC1 2602/4885 |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | EPHX1, LTA4H, PTGS1 | EPHX1 1/4885EPHX2 4/4885NPC1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.